We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement
News

Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement

Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement
News

Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Santhera and Ipsen Renegotiate Fipamezole Licensing Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Santhera Pharmaceuticals and Ipsen have announced that they have renegotiated their fipamezole licensing agreement.

Santhera regains the worldwide rights to the development and commercialization of fipamezole, its first-in-class selective adrenergic alpha-2 receptor antagonist for the management of levodopa-induced Dyskinesia in Parkinson's Disease.

Under the renegotiated terms, Ipsen returns its rights for territories outside of North America and Japan in exchange for milestone payments and royalties based on future partnering and commercial success of fipamezole.

Ipsen retains a call option for worldwide license to the program under certain conditions.

Thomas Meier, Chief Executive Officer of Santhera, commented: "Under the agreement reached with Ipsen, Santhera has regained global marketing rights for fipamezole, which we can further develop in line with the Company's strategy. In the short term, the focus of our investments remains on our lead product Catena® and its multiple product opportunities in neuromuscular and mitochondrial orphan indications. However, fipamezole continues to be a valuable asset in Santhera's late-stage clinical pipeline."

Pierre Boulud, Ipsen's Executive Vice-President, Corporate Strategy stated: "We are pleased that Santhera regains the worldwide rights to an agent like fipamezole. This new agreement will help to leverage the drug's value on a global basis while allowing Ipsen to focus on its rich late stage development pipeline. With its important commercial overlap with movement disorders, Parkinson Disease remains an important area of commercial focus for Ipsen. Santhera's commitment to this first-in-class drug has the potential to benefit levodopa-induced dyskinesia in Parkinson's Disease patients in crucial need of better therapies."

Advertisement